As shown in Additional file 2: Figure S1-S4 and Additional file 1: Table S2-S5, the benchmark analysis with 400 AR and AD genes, the analyses of the impacts of patient cohort size, population stratification, and variant frequency filtering all showed that the results based on DANN and REVEL scores are consistent with the previous results based on CADD score. This evidence concerns the gene AR and Alzheimer disease.